基于半体内法研究利胆排毒方抗内毒素活性部位

Study on the Anti-endotoxin Active Parts of Lidanpaidu Prescription Based on a Half-in vivo Method

目的:观察利胆排毒方活性部位半体内抗内毒素作用强度,进一步确认抗内毒素作用的活性部位。方法:利胆排毒方提取液采用不同极性溶剂进行萃取,获取活性部位。采用偶氮化显色基质法测定该部位抗内毒素活性,比较不同剂量组不同提取部位的内毒素灭活量。结果:各给药组大鼠血浆对内毒素灭活量均高于空白对照组,差异有统计学意义(P<0.05);全方提取液各剂量组给药大鼠血浆对内毒素有灭活作用,但组间差异无统计学意义(P>0.05);水溶性部位给药大鼠血浆各组也表现出对内毒素的灭活作用,且高剂量组与低剂量组差异有统计学意义(P<0.05)。结论:半体内抗内毒素作用实验结果可见水溶性部位抗内毒素作用与全方提取液相当,且初步呈现出一定的量效关系,则水溶性部位很大程度上保留了全方提取液的有效成分,可进一步确认为利胆排毒方抗内毒素活性部位。

Objective： To further confirm the anti-endotoxin active parts of Lidanpaidu prescription through observing the anti-en- dotoxin intensity based on a half-in vivo method. Methods： The extracting solution of Lidanpaidu prescription was extracted by the sol- vents with different polarity to obtain the active part. The anti-endotoxin activity of the samples was determined by using the Azo color matrix method, and the amount of inactivated endotoxin was compared among the various extraction parts with different dosages. Re- stilts： Compared with that of the control group, the amount of inactivated endotoxin by the rat plasma in each administration group was all higher, and the differences were statistically significant （P 〈 0.05 ）. The rat plasma of the whole prescription administration groups all showed endotoxin inactivation, while the differences among the groups with various dosages were without statistical significance（ P 〉 0.05 ）. The rat plasma of the water soluble fraction administration groups also showed endotoxin inactivation, and the difference be- tween the high dosage group and the low dosage group was statistically significant （ P 〈 0.05 ）. Conclusion： The results of the half-in vivo method showed the consistent anti-endotoxin effect of the whole prescription and the water soluble fraction, furthermore, the dose- effect relationship is preliminarily appeared, suggesting that the water soluble fraction remains the effective components of the whole prescription to a great extent. Therefore, the water soluble fraction can be further confirmed as the active anti-endotoxin part of Lidan- paidu prescription.